{{Drugbox
| verifiedrevid = 444759950
| IUPAC_name = ''N'',''N''-dimethyl-2,2-diphenoxyethanamine
| image = Medifoxamine Structural Formulae.png
| width = 200px

<!--Clinical data-->
| tradename = Clédial, Gerdaxyl
| pregnancy_category = 
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|By mouth]]

<!--Pharmacokinetic data-->
| bioavailability = 21%<ref name="SalehJohnston1990">{{cite journal|last1=Saleh|first1=S|last2=Johnston|first2=A|last3=Turner|first3=P|title=Absolute bioavailability and pharmacokinetics of medifoxamine in healthy humans.|journal=British Journal of Clinical Pharmacology|volume=30|issue=4|year=1990|pages=621–624|issn=0306-5251|doi=10.1111/j.1365-2125.1990.tb03823.x}}</ref><ref name="Dörwald2013">{{cite book|author=Florencio Zaragoza Dörwald|title=Lead Optimization for Medicinal Chemists: Pharmacokinetic Properties of Functional Groups and Organic Compounds|url=https://books.google.com/books?id=YTeY9ZEfNccC&pg=PA259|date=4 February 2013|publisher=John Wiley & Sons|isbn=978-3-527-64565-7|pages=259–}}</ref>
| metabolism = 
| elimination_half-life = 2.8 hours (acute);<ref name="SalehJohnston1990" /><ref name="Dörwald2013" /><br /> 4.0 hours (chronic)<ref name="pmid8039537">{{cite journal | vauthors = Gainsborough N, Nelson ML, Maskrey V, Swift CG, Jackson SH | title = The pharmacokinetics and pharmacodynamics of medifoxamine after oral administration in healthy elderly volunteers | journal = Eur. J. Clin. Pharmacol. | volume = 46 | issue = 2 | pages = 163–6 | year = 1994 | pmid = 8039537 | doi = 10.1007/bf00199882| url = }}</ref>
| excretion = 

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 32359-34-5
| CAS_supplemental = <br />16604-45-8 ([[fumarate]])<br />16604-44-7 ([[picrate]])
| ATC_prefix = N06
| ATC_suffix = AX13
| PubChem = 36109
| ChemSpiderID = 33212
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = KWU7C2A1NT
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07341
| synonyms = Medifoxamine fumarate; ''N'',''N''-Dimethyl-2,2-diphenoxyethylamine

<!--Chemical data-->
| C=16 | H=19 | N=1 | O=2
| molecular_weight = 257.328 g/mol
| SMILES = CN(C)CC(OC1=CC=CC=C1)OC2=CC=CC=C2
| StdInChI = 1S/C16H19NO2/c1-17(2)13-16(18-14-9-5-3-6-10-14)19-15-11-7-4-8-12-15/h3-12,16H,13H2,1-2H3
| StdInChIKey = QNMGHBMGNRQPNL-UHFFFAOYSA-N
| chirality = [[Racemic mixture]]
}}

'''Medifoxamine''', previously sold under the brand names '''Clédial''' and '''Gerdaxyl''', is an [[atypical antidepressant]]<ref name="Holroyd-LeducReddy2012">{{cite book|author1=Jayna Holroyd-Leduc|author2=Madhuri Reddy|title=Evidence-Based Geriatric Medicine|url=https://books.google.com/books?id=VfPIUfcwrFkC&pg=PT299|date=9 March 2012|publisher=John Wiley & Sons|isbn=978-1-118-28181-9|pages=299–}}</ref> with additional [[anxiolytic]] properties<ref>{{cite book|title=ANNUAL REPORTS IN MED CHEMISTRY V22 PPR|url=https://books.google.com/books?id=oJeTSJveeuAC&pg=PA323|date=2 September 1987|publisher=Academic Press|isbn=978-0-08-058366-2|pages=323–}}</ref> acting via [[dopaminergic]] and [[serotonergic]] mechanisms which was formerly marketed in [[France]] and [[Spain]], as well as [[Morocco]].<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA759|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=759–}}</ref><ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA638|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=638–}}</ref><ref name="MortonHall1999">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=mqaOMOtk61IC&pg=PA173|date=31 October 1999|publisher=Springer Science & Business Media|isbn=978-0-7514-0499-9|pages=173–}}</ref><ref name="pmid8668756">{{cite journal | vauthors = Mitchell PB | title = Novel French antidepressants not available in the United States | journal = Psychopharmacol Bull | volume = 31 | issue = 3 | pages = 509–19 | year = 1995 | pmid = 8668756 | doi = | url = }}</ref><ref name="UnitedNations2003">{{cite book|title=Consolidated List of Products Whose Consumption And/or Sale Have Been Banned, Withdrawn, Severely Restricted Or Not Approved by Governments|url=https://books.google.com/books?id=leVCukUgNlsC&pg=PA135|year=2003|publisher=United Nations Publications|isbn=978-92-1-130230-1|pages=135–136}}</ref> The drug was first introduced in France sometime around 1990.<ref name="pmid2380545">{{cite journal | vauthors = Saleh S, Johnston A, Edeki T, Turner P | title = Tolerability and kinetics of intravenous medifoxamine in healthy volunteers | journal = Int Clin Psychopharmacol | volume = 5 | issue = 2 | pages = 97–102 | year = 1990 | pmid = 2380545 | doi = 10.1097/00004850-199004000-00003| url = }}</ref> It was [[Withdrawn drug|withdrawn]] from the market in 1999 (Morocco) and 2000 (France) following incidences of [[hepatotoxicity]].<ref name="UnitedNations2003" /><ref name="pmid12506267">{{cite journal | vauthors = Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, Aubriot-Delmas B, Glikman J, Januel D | title = [Hepatic tolerance of atypical antipsychotic drugs] | language = French | journal = Encephale | volume = 28 | issue = 6 Pt 1 | pages = 542–51 | year = 2002 | pmid = 12506267 | doi = | url = }}</ref><ref name="PapakostasFava2010">{{cite book|author1=George I. Papakostas|author2=Maurizio Fava|title=Pharmacotherapy for Depression and Treatment-resistant Depression|url=https://books.google.com/books?id=zigp-66vq0MC&pg=PA88|year=2010|publisher=World Scientific|isbn=978-981-4287-59-3|pages=88–}}</ref>

{{TOC limit|3}}

==Pharmacology==

===Pharmacodynamics===
Medifoxamine has been found to act preferentially as a relatively weak [[dopamine reuptake inhibitor]],<ref name="pmid8039537" /><ref name="SalehTurner1992">{{cite journal|last1=Saleh|first1=S|last2=Turner|first2=P|title=Ocular hypotensive effects of medifoxamine.|journal=British Journal of Clinical Pharmacology|volume=34|issue=3|year=1992|pages=269–271|issn=0306-5251|doi=10.1111/j.1365-2125.1992.tb04136.x}}</ref><ref name="VaugeoisPouhé1994">{{cite journal|last1=Vaugeois|first1=J.-M.|last2=Pouhé|first2=D.|last3=Lemonnier|first3=F.|last4=Costentin|first4=J.|title=Neurochemical and behavioral evidence for a central indirect dopaminergic agonist activity of the antidepressant medifoxamine in mice|journal=European Neuropsychopharmacology|volume=4|issue=3|year=1994|pages=323–324|issn=0924-977X|doi=10.1016/0924-977X(94)90140-6}}</ref><ref name="Berk2000">{{cite journal|last1=Berk|first1=Michael|title=Depression therapy: Future prospects|journal=International Journal of Psychiatry in Clinical Practice|volume=4|issue=4|year=2000|pages=281–286|issn=1365-1501|doi=10.1080/13651500050517830}}</ref> but also as an even weaker [[serotonin reuptake inhibitor]] ([[IC50|IC<sub>50</sub>]] = 1,500&nbsp;nM)<ref name="pmid8039537" /> and as a weak [[receptor antagonist|antagonist]] of the [[5-HT2A receptor|5-HT<sub>2A</sub>]] and [[5-HT2C receptor|5-HT<sub>2C</sub> receptor]]s (IC<sub>50</sub> = 950 and 980, respectively; notably greater [[affinity (pharmacology)|affinity]] relative to [[amitriptyline]] and [[imipramine]]).<ref name="pmid8039537" /><ref name="pmid7988407">{{cite journal | vauthors = Martin P, Lemonnier F | title = [The role of type 2 serotonin receptors, 5-HT2A and 5-HT2C, in depressive disorders: effect of medifoxamine] | language = French | journal = Encephale | volume = 20 | issue = 4 | pages = 427–35 | year = 1994 | pmid = 7988407 | doi = | url = }}</ref><ref name="pmid8275921">{{cite journal | vauthors = Olié JP, Galinowski A, Lehert P, Lemonnier F, Lôo H | title = [Randomized double-blind comparative study of the efficacy and tolerance of medifoxamine and imipramine in depressed patients] | language = French | journal = Encephale | volume = 19 | issue = 4 | pages = 333–40 | year = 1993 | pmid = 8275921 | doi = | url = }}</ref> It is known to produce two [[active metabolite]]s during [[first-pass metabolism]] in the [[liver]], [[CRE-10086]] (N-methyl-2,2-diphenoxyethylamine) and [[CRE-10357]] (N,N-dimethyl-2-hydroxyphenoxy-2-phenoxyethylamine).<ref name="pmid8039537" /> The IC<sub>50</sub> values of CRE-10086 for [[serotonin transporter]], 5-HT<sub>2A</sub>, and 5-HT<sub>2C</sub> binding are 450&nbsp;nM, 330&nbsp;nM, and 700&nbsp;nM, respectively, while those of CRE-10357 are 660&nbsp;nM, 1,600&nbsp;nM, and 6,300 &nbsp;M.<ref name="pmid8039537" /> Medifoxamine and its metabolites lack affinity for other [[serotonin receptor]]s including [[5-HT1A receptor|5-HT<sub>1A</sub>]], [[5-HT1B receptor|5-HT<sub>1B</sub>]], [[5-HT1D receptor|5-HT<sub>1D</sub>]], and [[5-HT3 receptor|5-HT<sub>3</sub>]] (>10,000&nbsp;nM).<ref name="pmid8039537" /> As medifoxamine is metabolized extensively in the liver during first-pass metabolism, and as these metabolites have as much as 3-fold greater activity relative to medifoxamine, it is likely that they contribute significantly to the [[pharmacology]] of the parent drug.<ref name="pmid8039537" />

====Effectiveness and tolerability====
Unlike many [[tricyclic antidepressant]]s, medifoxamine lacks [[anticholinergic]] and [[alpha blocker]] properties (very low affinity for the [[muscarinic acetylcholine receptor]]s and 10-fold lower affinity for the [[α1-adrenergic receptor|α<sub>1</sub>-adrenergic receptor]] relative to 5-HT<sub>2</sub> binding sites),<ref name="pmid8039537" /><ref name="SalehTurner1992" /><ref name="RandhawaHedges1988">{{cite journal|last1=Randhawa|first1=M. A.|last2=Hedges|first2=A.|last3=Johnston|first3=A.|last4=Turner|first4=P.|title=A psychopharmacological study to assess anti-muscarinic and central nervous effects of medifoxamine in normal volunteers|journal=Human Psychopharmacology: Clinical and Experimental|volume=3|issue=3|year=1988|pages=195–200|issn=0885-6222|doi=10.1002/hup.470030307}}</ref> and is also apparently inactive as a [[norepinephrine reuptake inhibitor]] (although the same source stating this also states that it is inactive as a serotonin reuptake inhibitor, which was subsequently found not to be the case).<ref>{{cite book|title=ANNUAL REPORTS IN MED CHEMISTRY V20 PPR|url=https://books.google.com/books?id=j-3Cd_SWIksC&pg=PA35|date=11 September 1985|publisher=Academic Press|isbn=978-0-08-058364-8|pages=35–}}</ref> Studies in mice revealed that the drug does not possess any [[sedative]] or [[stimulant|locomotor stimulant]] effects.<ref name="pmid8039537" /> In accordance with all of the preceding, medifoxamine was found to be [[drug tolerability|well-tolerated]] at dosages of 100–300&nbsp;mg per day in [[clinical trial]]s.<ref name="pmid8039537" /> [[Double-blind]] [[controlled study|controlled]] [[Clinical trial|clinical studies]] have found it to have similar effectiveness to imipramine, [[clomipramine]], and [[maprotiline]] in the treatment of [[depression (mood)|depression]].<ref name="pmid8039537" /><ref name="pmid8668756" /><ref name="pmid8275921" /><ref name="RandhawaHedges1988" />

==Society and culture==

===Generic names===
''Medifoxamine'' is the [[generic term|generic name]] of the drug and its {{abbrlink|INN|International Nonproprietary Name}} while ''médifoxamine'' is its {{abbrlink|DCF|Dénomination Commune Française}}.<ref name="Elks2014" /><ref name="IndexNominum2000" /><ref name="MortonHall1999" />

===Brand names===
Medifoxamine was marketed under the brand names Clédial and Gerdaxyl.<ref name="Elks2014" /><ref name="IndexNominum2000" />

==References==
{{Reflist|30em}}


{{Antidepressants}}
{{Monoamine reuptake inhibitors}}
{{Serotonin receptor modulators}}

[[Category:5-HT2A antagonists]]
[[Category:5-HT2C antagonists]]
[[Category:Amines]]
[[Category:Anxiolytics]]
[[Category:Bicyclic antidepressants]]
[[Category:Hepatotoxins]]
[[Category:Phenol ethers]]
[[Category:Serotonin-dopamine reuptake inhibitors]]
[[Category:Withdrawn drugs]]